胰臟癌精准医疗市场规模、份额、趋势分析报告：按治疗方法、诊断技术、地区和细分趋势：2025-2030 年

胰臟癌精准医疗市场的成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2030年全球胰臟癌精准医疗市场规模将达到18.8亿美元，预测期内复合年增长率为19.2%。

由于越来越多地采用标靶治疗和免疫疗法来提高存活率并最大限度地减少副作用，胰臟癌精准医疗产业正在经历成长。先进的诊断工具，包括液态切片和分子分析，改善了早期检测和治疗结果。这种向精准医疗的转变促进了更有效和个人化的治疗策略。

技术进步，特别是次世代定序仪和生物资讯学的整合，促进了新治疗标靶的发现，并实现了更有效的药物设计。製药公司、学术机构和政府机构加大投入，支持创新治疗方法的开发。 PanCAN津贴计划等倡议已显示了资助胰臟癌研究的承诺，从而推动了市场成长。

受生活方式因素和人口老化的影响，胰臟癌发生率不断上升，对专门治疗的需求很高。澳洲癌症协会估计，到 2024 年，全国将诊断出 4,641 例新的胰臟癌病例。盛行率的上升促使医疗保健提供者寻求更有效的选择，从而推动了市场的成长。此外，製药公司和研究机构之间的策略联盟以及监管机构的支持进一步加速了市场的成长。

胰臟癌精准医疗市场报告重点

• 根据治疗方法，标靶治疗将占据市场主导地位，到 2024 年将占 56.0% 的份额。
• 另一方面，化疗和精准联合治疗预计在预测期内将以最快的复合年增长率成长。
• 从诊断技术来看，基因组检测将引领市场，到 2024 年将占 40.8%。事实证明，其在识别可操作突变方面的作用对于个人化治疗至关重要。
• 液态生物检体是一种透过 ctDNA 和 CTC 分析进行早期检测的微创方法，由于患者治疗效果的改善，预计在预测期内将以 20.3% 的最快复合年增长率增长。
• 标靶治疗和免疫治疗的采用日益增多，加上先进的诊断技术，透过提高存活率和製定有效的精准医疗策略，推动了市场的成长。
• 受高发病率和对有效治疗的需求推动，北美在全球胰腺癌精准医疗行业中占据主导地位，收入份额为 42.9%。
• 胰臟癌精准医疗产业的市场参与企业包括阿斯特捷利康、辉瑞公司、诺华公司、安进公司、罗氏公司、拜耳公司、礼来公司、默克公司、梯瓦製药工业有限公司、PharmaCyte Biotech 公司、基因泰克公司、Guardant Health、Illumina 公司、赛默飞世尔科技公司和 FOUNDATIONDICINE FOUND。
• 2024年8月，Illumina公司为NovaSeq X系列客户推出了新的肿瘤学菜单，以更低的成本、更大规模地为全球客户扩展全面的基因组分析。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章胰臟癌精准医疗市场变数、趋势与范围

• 市场体系展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析—波特五力分析
  • PESTLE分析

第四章胰臟癌精准医疗市场：治疗方法业务分析

• 2024 年和 2030 年治疗方法市场占有率
• 治疗方法细分仪表板
• 2018 年至 2030 年按治疗方法分類的市场规模、预测和趋势分析
• 标靶治疗
• PARP 抑制剂
• 单株抗体
• 小分子抑制剂－EGFR抑制剂、KRAS抑制剂
• 免疫疗法
• 免疫查核点抑制剂－PD-1抑制剂、PD-L1抑制剂
• 癌症疫苗-GVAX、Argenpantusel-L
• 过继性T细胞疗法-CAR-T疗法
• 精准化疗组合
• 其他的

第五章胰臟癌精准医疗市场：诊断技术业务分析

• 2024 年和 2030 年诊断市场占有率
• 诊断技术细分仪表板
• 2018 年至 2030 年诊断技术市场规模、预测与趋势分析
• 基因组检测
• 分子诊断
• 液态生物检体
• 基于生物标记的伴同性诊断
• 其他（免疫组织化学（IHC）、蛋白质体学、质谱分析）

第六章 胰臟癌精准医疗市场：按地区估计和趋势分析

• 2024 年及 2030 年区域市场占有率分析
• 区域市场仪表板
• 2018-2030 年市场规模及预测趋势分析
• 北美洲
  • 按国家/地区，2018 年至 2030 年
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 2018-2030年各国情况
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 挪威
  • 丹麦
  • 瑞典
• 亚太地区
  • 2018-2030年各国情况
  • 日本
  • 中国
  • 印度
  • 韩国
  • 澳洲
  • 泰国
• 拉丁美洲
  • 2018-2030年各国情况
  • 巴西
  • 阿根廷
• 中东和非洲
  • 2018-2030年各国情况
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第七章 竞争格局

• 参与者概述
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • PharmaCyte BIoTech, Inc.
  • Genentech, Inc.
  • Guardant Health
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • FOUNDATION MEDICINE, INC.

Pancreatic Cancer Precision Medicine Market Growth & Trends:

The global pancreatic cancer precision medicine market size is anticipated to reach USD 1.88 billion by 2030, registering a CAGR of 19.2% during the forecast period, according to a new report by Grand View Research, Inc. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.

Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.

The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.

Pancreatic Cancer Precision Medicine Market Report Highlights:

• Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
• Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
• Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
• Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
• The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
• North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
• Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
• In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Approach
  • 1.2.2. Diagnostic Technology
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pancreatic Cancer Precision Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Business Analysis

• 4.1. Therapeutic Approach Market Share, 2024 & 2030
• 4.2. Therapeutic Approach Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Approach, 2018 to 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.5. PARP Inhibitors
  • 4.5.1. PARP Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. Monoclonal Antibodies
  • 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
• 4.7. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
  • 4.7.1. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. Immunotherapy
  • 4.8.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.9. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
  • 4.9.1. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.10. Cancer Vaccines - GVAX, Algenpantucel-L
  • 4.10.1. Cancer Vaccines - GVAX, Algenpantucel-L Market, 2018 - 2030 (USD Million)
• 4.11. Adoptive T-Cell Therapies - CAR-T Therapies
  • 4.11.1. Adoptive T-Cell Therapies - CAR-T Therapies Market, 2018 - 2030 (USD Million)
• 4.12. Chemotherapy-Precision Combinations
  • 4.12.1. Chemotherapy-Precision Combinations Market, 2018 - 2030 (USD Million)
• 4.13. Other Therapeutic Approaches
  • 4.13.1. Other Therapeutic Approaches Market, 2018 - 2030 (USD Million)

Chapter 5. Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Business Analysis

• 5.1. Diagnostic Technology Market Share, 2024 & 2030
• 5.2. Diagnostic Technology Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Diagnostic Technology, 2018 to 2030 (USD Million)
• 5.4. Genomic Testing
  • 5.4.1. Genomic Testing Market, 2018 - 2030 (USD Million)
• 5.5. Molecular Diagnostics
  • 5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
• 5.6. Liquid Biopsy
  • 5.6.1. Liquid Biopsy Market, 2018 - 2030 (USD Million)
• 5.7. Biomarker-based Companion Diagnostics
  • 5.7.1. Biomarker-based Companion Diagnostics Market, 2018 - 2030 (USD Million)
• 5.8. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
  • 5.8.1. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry) Market, 2018 - 2030 (USD Million)

Chapter 6. Pancreatic Cancer Precision Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AstraZeneca
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amgen Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Bayer AG
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Eli Lilly and Company
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Merck & Co., Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Teva Pharmaceutical Industries Ltd
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. PharmaCyte Biotech, Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Genentech, Inc.
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Guardant Health
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. Illumina, Inc.
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. Thermo Fisher Scientific Inc.
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic Initiatives
  • 7.5.15. FOUNDATION MEDICINE, INC.
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global pancreatic cancer precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 4 Global pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 5 Global pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 6 North America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 7 North America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 8 North America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 9 U.S. pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 10 U.S. Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 11 Canada pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 12 Canada pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 13 Mexico pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 14 Mexico pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 15 Europe pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 17 Europe pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 18 UK pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 19 UK Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 20 Germany pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 21 Germany pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 22 France pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 23 France Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 24 Italy pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 25 Italy pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 26 Spain pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 27 Spain pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 28 Norway pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 29 Norway Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 30 Denmark pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 31 Denmark pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 32 Sweden pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 33 Sweden pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 37 Japan pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 38 Japan pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 39 China pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 40 China pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 41 India pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 42 India pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 43 Australia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 44 Australia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 45 South Korea pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 46 South Korea pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 47 Thailand pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 48 Thailand pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 49 Latin America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 51 Latin America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 52 Brazil pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 53 Brazil pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 54 Argentina pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 55 Argentina pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 59 South Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 60 South Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 63 UAE pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 64 UAE pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 65 Kuwait pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 66 Kuwait pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pancreatic cancer precision medicine market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and diagnostic technology outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Pancreatic cancer precision medicine market dynamics
• Fig. 12 Pancreatic cancer precision medicine market: Porter's five forces analysis
• Fig. 13 Pancreatic cancer precision medicine market: PESTLE analysis
• Fig. 14 Pancreatic cancer precision medicine market: Therapeutic approach segment dashboard
• Fig. 15 Pancreatic cancer precision medicine market: Therapeutic approach market share analysis, 2024 & 2030
• Fig. 16 Targeted therapy market, 2018 - 2030 (USD Million)
• Fig. 17 PARP inhibitors market, 2018 - 2030 (USD Million)
• Fig. 18 Monoclonal antibodies market, 2018 - 2030 (USD Million)
• Fig. 19 Small molecule inhibitors - EGFR inhibitors, KRAS inhibitors market, 2018 - 2030 (USD Million)
• Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
• Fig. 21 Immune checkpoint inhibitors - PD-1 inhibitors, PD-L1 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 22 Cancer vaccines - GVAX, Algenpantucel-L market, 2018 - 2030 (USD Million)
• Fig. 23 Adoptive T-Cell therapies - CAR-T therapies market, 2018 - 2030 (USD Million)
• Fig. 24 Chemotherapy-precision combinations market, 2018 - 2030 (USD Million)
• Fig. 25 Other therapeutic approaches market, 2018 - 2030 (USD Million)
• Fig. 26 Pancreatic cancer precision medicine market: Diagnostic technology segment dashboard
• Fig. 27 Pancreatic cancer precision medicine market: Diagnostic technology market share analysis, 2024 & 2030
• Fig. 28 Genomic testing market, 2018 - 2030 (USD Million)
• Fig. 29 Molecular diagnostics market, 2018 - 2030 (USD Million)
• Fig. 30 Liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 31 Biomarker-based companion diagnostics market, 2018 - 2030 (USD Million)
• Fig. 32 Others (Immunohistochemistry (IHC), proteomics, mass spectrometry) market, 2018 - 2030 (USD Million)
• Fig. 33 Pancreatic cancer precision medicine market revenue, by region
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 North America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. country dynamics
• Fig. 38 U.S. pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 39 Canada country dynamics
• Fig. 40 Canada pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 41 Mexico country dynamics
• Fig. 42 Mexico pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 43 Europe pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 44 UK country dynamics
• Fig. 45 UK pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 46 Germany country dynamics
• Fig. 47 Germany pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 48 France country dynamics
• Fig. 49 France pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 50 Italy country dynamics
• Fig. 51 Italy pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 52 Spain country dynamics
• Fig. 53 Spain pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 54 Norway country dynamics
• Fig. 55 Norway pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 56 Sweden country dynamics
• Fig. 57 Sweden pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 58 Denmark country dynamics
• Fig. 59 Denmark pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 60 Asia Pacific pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 61 Japan country dynamics
• Fig. 62 Japan pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 63 China country dynamics
• Fig. 64 China pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 65 India country dynamics
• Fig. 66 India pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 67 Australia country dynamics
• Fig. 68 Australia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 69 South Korea country dynamics
• Fig. 70 South Korea pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 71 Thailand country dynamics
• Fig. 72 Thailand pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 73 Latin America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 74 Brazil country dynamics
• Fig. 75 Brazil pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 76 Argentina country dynamics
• Fig. 77 Argentina pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 78 MEA pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 79 South Africa country dynamics
• Fig. 80 South Africa pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 81 Saudi Arabia country dynamics
• Fig. 82 Saudi Arabia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 83 UAE country dynamics
• Fig. 84 UAE pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 85 Kuwait country dynamics
• Fig. 86 Kuwait pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 87 Company categorization
• Fig. 88 Company market position analysis
• Fig. 89 Strategic framework